TD Cowen Increases United Therapeutics (NASDAQ:UTHR) Price Target to $400.00

United Therapeutics (NASDAQ:UTHR) had its price objective boosted by equities researchers at TD Cowen from $350.00 to $400.00 in a research note issued on Monday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. TD Cowen’s price objective would indicate a potential upside of 8.03% from the stock’s current price.

A number of other research firms also recently issued reports on UTHR. Oppenheimer raised their target price on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. Jefferies Financial Group raised their target price on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Bank of America decreased their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. Morgan Stanley downgraded United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the stock from $310.00 to $321.00 in a research report on Thursday, July 11th. Finally, StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $361.33.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $370.26 on Monday. The business’s fifty day simple moving average is $351.40 and its 200 day simple moving average is $309.96. The firm has a market capitalization of $16.47 billion, a P/E ratio of 17.02, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57. United Therapeutics has a 12 month low of $208.62 and a 12 month high of $377.03. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The business had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business’s revenue was up 19.8% compared to the same quarter last year. During the same quarter last year, the business posted $5.24 earnings per share. As a group, analysts anticipate that United Therapeutics will post 24.72 EPS for the current year.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 7,782 shares of United Therapeutics stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $366.99, for a total transaction of $2,855,916.18. Following the completion of the sale, the chief financial officer now owns 6,426 shares of the company’s stock, valued at $2,358,277.74. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other United Therapeutics news, CFO James Edgemond sold 7,782 shares of United Therapeutics stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $366.99, for a total transaction of $2,855,916.18. Following the completion of the sale, the chief financial officer now owns 6,426 shares of the company’s stock, valued at $2,358,277.74. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael Benkowitz sold 25,000 shares of United Therapeutics stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total value of $8,084,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $833,350.26. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 106,412 shares of company stock worth $36,470,922 over the last ninety days. 11.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Hennion & Walsh Asset Management Inc. lifted its stake in shares of United Therapeutics by 31.4% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 4,286 shares of the biotechnology company’s stock valued at $1,536,000 after acquiring an additional 1,023 shares during the last quarter. First National Bank of Hutchinson lifted its stake in shares of United Therapeutics by 46.3% in the 3rd quarter. First National Bank of Hutchinson now owns 2,481 shares of the biotechnology company’s stock valued at $889,000 after acquiring an additional 785 shares during the last quarter. International Assets Investment Management LLC lifted its stake in shares of United Therapeutics by 140,617.1% in the 3rd quarter. International Assets Investment Management LLC now owns 57,694 shares of the biotechnology company’s stock valued at $20,675,000 after acquiring an additional 57,653 shares during the last quarter. Lecap Asset Management Ltd. bought a new stake in shares of United Therapeutics in the 3rd quarter valued at about $482,000. Finally, Signaturefd LLC lifted its stake in shares of United Therapeutics by 8.8% in the 3rd quarter. Signaturefd LLC now owns 633 shares of the biotechnology company’s stock valued at $227,000 after acquiring an additional 51 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.